30988 research outputs found
Sort by
Professional Competence of AI Experts: A Qualitative Content Analysis of Job Descriptions and Skill Requirements in AI-Related Expert Roles
The European Language Portfolio’s (ELP) Influence on Primary Students’ Intercultural Awareness (ICA): Perspectives of Language Teachers in Finland
The Impact of Smoking on the Prognosis of Lung Cancer Patients and the Use of Specialised Healthcare Resources
Lisääntyvätkö lonkkamurtumat?
• Lonkkamurtuma on osteoporoosin merkittävin päätetapahtuma. Se kasvattaa terveydenhuollon kustannuksia ja lisää ylikuolleisuutta.
• Murtumien määrä suurenee väestön ikääntyessä, joskin ilmaantuvuuden kasvun on todettu tasaantuvan.
• Murtumien ehkäisyssä osteoporoosin hoito ja kaatumisten välttäminen ovat avainasemassa
Mechanism of biomimetic virus-like nanoparticles in triggering immune response elucidated by proteomics
The use of biomimetic nanoparticles (NPs) with virus-like morphology have recently attracted research interest as novel delivery platforms and immune adjuvants. However, the exact interactions between the nanoparticles and immune cells as well as the mechanism involved are not known in detail. This motivated us to develop virus-like mesoporous silica nanoparticles (VLP) to characterize their physicochemical properties, and to determine the immune pathways induced by the particles in mouse macrophages. The results showed inclusion of spikes mimicking viral structures on the surface increased cellular uptake and enhanced immune response as compared to spherical NPs. Proteomic analysis revealed that the pathways of RIG-I-like receptor signaling, MAPK, NF-κB, and Toll-like receptor signaling were involved in regulating the immune response when macrophages interacted with VLP. When the spikes increased from 5 to 30 nm, the expression of immune-related proteins including TRAF6 and PIAS4 proteins was upregulated. This study revealed the interaction pathways and key proteins in the activation of immune response with VLP, which may provide insights to develop novel immunotherapy for enhanced efficacy